Michael Higgins
Stock Analyst at Ladenburg Thalmann
(1.76)
# 3,333
Out of 5,042 analysts
21
Total ratings
29.41%
Success rate
5.55%
Average return
Main Sectors:
Stocks Rated by Michael Higgins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Downgrades: Neutral | n/a | $23.63 | - | 4 | May 9, 2024 | |
| FBRX Forte Biosciences | Upgrades: Buy | $69 | $12.94 | +431.30% | 3 | Apr 8, 2024 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $7 | $1.39 | +403.60% | 1 | May 2, 2023 | |
| SCYX SCYNEXIS | Reiterates: Buy | $15 | $0.66 | +2,172.73% | 1 | Apr 3, 2023 | |
| ARTL Artelo Biosciences | Reiterates: Buy | $360 | $3.10 | +11,512.90% | 2 | Apr 3, 2023 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $113.76 | -69.23% | 3 | Mar 2, 2023 | |
| PHGE BiomX | Maintains: Buy | $130 → $80 | $0.49 | +16,094.33% | 2 | May 12, 2022 | |
| NVAX Novavax | Downgrades: Sell | $105 | $8.40 | +1,150.00% | 2 | Aug 5, 2020 | |
| VIRT Virtu Financial | Upgrades: Buy | $29 | $34.84 | -16.76% | 2 | Jan 4, 2019 | |
| SVRA Savara | Reinstates: Buy | n/a | $4.15 | - | 1 | Sep 27, 2017 |
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $23.63
Upside: -
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $69
Current: $12.94
Upside: +431.30%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $1.39
Upside: +403.60%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $0.66
Upside: +2,172.73%
Artelo Biosciences
Apr 3, 2023
Reiterates: Buy
Price Target: $360
Current: $3.10
Upside: +11,512.90%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $113.76
Upside: -69.23%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $130 → $80
Current: $0.49
Upside: +16,094.33%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: $105
Current: $8.40
Upside: +1,150.00%
Virtu Financial
Jan 4, 2019
Upgrades: Buy
Price Target: $29
Current: $34.84
Upside: -16.76%
Savara
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $4.15
Upside: -